(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
15 June 2006 (15.06.2006)

PCT

(10) International Publication Number
WO 2006/061253 A3

(51) International Patent Classification:
A61K 39/00 (2006.01) *A61P 35/00* (2006.01)
A61K 31/517 (2006.01)

(21) International Application Number:
PCT/EP2005/013409

(22) International Filing Date:
8 December 2005 (08.12.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0427131.8 10 December 2004 (10.12.2004) GB

(71) Applicant *(for all designated States except US)*: **GLAXOSMITHKLINE BIOLOGICALS S.A.** [BE/BE]; Rue de l'Institut, 89, B-1330 Rixensart (BE).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **BRUCK, Claudine, Elvire, Marie** [LU/US]; GlaxoSmithkline, 709 Swedeland Road, King of Prussia, PA 19406 (US). **GERARD, Catherine, Marie, Ghislaine** [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE).

(74) Agent: **LOVATT, Victoria, Jayne**; GlaxoSmithKline, Corporate Intellectual Property, (CN925.1), 980 Great West Road, Brentford, Middlesex, TW8 9GS (GB).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

[Continued on next page]

(54) **Title:** COMBINATION OF TYROSINE KINASE INHIBITOR AND HER-2/NEU FOR CANCER THERAPY



(57) **Abstract:** A method of treating cancer is described comprising administration of a 4quinazolineamine and a vaccine targeting the HER-2/neu molecule, as well as a pharmaceutical combination comprising 4-quinazolineamines and a vaccine targeting the HER-2/neu molecule.

WO 2006/061253 A3

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report*

(88) Date of publication of the international search report:
16 November 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.